Ernexa Therapeutics (ERNA) Competitors

Ernexa Therapeutics logo
$1.69 +0.01 (+0.60%)
Closing price 03:58 PM Eastern
Extended Trading
$1.74 +0.05 (+2.96%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ERNA vs. TCRX, BOLT, HIND, SYBX, and LSTA

Should you buy Ernexa Therapeutics stock or one of its competitors? Ernexa Therapeutics's main competitors and comparable companies include TScan Therapeutics (TCRX), Bolt Biotherapeutics (BOLT), Vyome (HIND), Synlogic (SYBX), and Lisata Therapeutics (LSTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ernexa Therapeutics compare to TScan Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Ernexa Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Ernexa Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ernexa Therapeutics$580K4.90-$14.08M-$12.49N/A
TScan Therapeutics$7.11M1.53-$129.77M-$0.88N/A

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 1,685.71%. TScan Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 1,560.44%. Given Ernexa Therapeutics' higher probable upside, equities research analysts clearly believe Ernexa Therapeutics is more favorable than TScan Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
TScan Therapeutics
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 13.8% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ernexa Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -2,219.19%. TScan Therapeutics' return on equity of -140.75% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ernexa TherapeuticsN/A -332.20% -187.38%
TScan Therapeutics -2,219.19%-140.75%-61.90%

In the previous week, TScan Therapeutics had 4 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for TScan Therapeutics and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.39 beat TScan Therapeutics' score of -0.37 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Ernexa Therapeutics Neutral
TScan Therapeutics Neutral

Summary

TScan Therapeutics beats Ernexa Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Bolt Biotherapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ernexa Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Ernexa Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 1,685.71%. Bolt Biotherapeutics has a consensus price target of $14.50, indicating a potential upside of 138.49%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bolt Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Ernexa Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -132.36% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ernexa TherapeuticsN/A -332.20% -187.38%
Bolt Biotherapeutics -611.47%-132.36%-53.78%

In the previous week, Bolt Biotherapeutics had 7 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 9 mentions for Bolt Biotherapeutics and 2 mentions for Ernexa Therapeutics. Bolt Biotherapeutics' average media sentiment score of 0.96 beat Ernexa Therapeutics' score of 0.39 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ernexa Therapeutics Neutral
Bolt Biotherapeutics Positive

Ernexa Therapeutics has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ernexa Therapeutics$580K4.90-$14.08M-$12.49N/A
Bolt Biotherapeutics$7.70M1.52-$33.38M-$16.44N/A

Summary

Bolt Biotherapeutics beats Ernexa Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Vyome?

Vyome (NASDAQ:HIND) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Vyome has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.75, indicating that its stock price is 175% more volatile than the broader market.

22.1% of Vyome shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vyome has higher earnings, but lower revenue than Ernexa Therapeutics. Vyome is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vyome$320K34.66-$10.26M-$3.37N/A
Ernexa Therapeutics$580K4.90-$14.08M-$12.49N/A

Vyome presently has a consensus target price of $3.50, suggesting a potential upside of 121.52%. Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 1,685.71%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Vyome.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vyome
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Ernexa Therapeutics has a net margin of 0.00% compared to Vyome's net margin of -958.58%. Vyome's return on equity of -60.15% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vyome-958.58% -60.15% -44.78%
Ernexa Therapeutics N/A -332.20%-187.38%

In the previous week, Vyome and Vyome both had 2 articles in the media. Vyome's average media sentiment score of 0.44 beat Ernexa Therapeutics' score of 0.39 indicating that Vyome is being referred to more favorably in the media.

Company Overall Sentiment
Vyome Neutral
Ernexa Therapeutics Neutral

Summary

Vyome beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Synlogic?

Ernexa Therapeutics (NASDAQ:ERNA) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Synlogic's return on equity of -26.47% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ernexa TherapeuticsN/A -332.20% -187.38%
Synlogic N/A -26.47%-18.00%

In the previous week, Ernexa Therapeutics and Ernexa Therapeutics both had 2 articles in the media. Synlogic's average media sentiment score of 1.50 beat Ernexa Therapeutics' score of 0.39 indicating that Synlogic is being referred to more favorably in the news media.

Company Overall Sentiment
Ernexa Therapeutics Neutral
Synlogic Very Positive

Ernexa Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ernexa Therapeutics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ernexa Therapeutics$580K4.90-$14.08M-$12.49N/A
Synlogic$8K1,684.24-$23.36M-$0.06N/A

Ernexa Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 1,685.71%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Ernexa Therapeutics is more favorable than Synlogic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Synlogic
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Ernexa Therapeutics beats Synlogic on 8 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Lisata Therapeutics had 4 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for Lisata Therapeutics and 2 mentions for Ernexa Therapeutics. Lisata Therapeutics' average media sentiment score of 0.65 beat Ernexa Therapeutics' score of 0.39 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Lisata Therapeutics Positive
Ernexa Therapeutics Neutral

Lisata Therapeutics' return on equity of -154.76% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -154.76% -120.19%
Ernexa Therapeutics N/A -332.20%-187.38%

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 8.4% of Lisata Therapeutics shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 1,685.71%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Lisata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Ernexa Therapeutics has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K76.87-$16.59M-$1.64N/A
Ernexa Therapeutics$580K4.90-$14.08M-$12.49N/A

Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market.

Summary

Ernexa Therapeutics beats Lisata Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ERNA vs. The Competition

MetricErnexa TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.86M$4.06B$7.83B$11.76B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-0.1424.2134.3230.12
Price / SalesN/A14.858.005.33
Price / CashN/A21.8921.0222.32
Price / Book0.224.354.763.85
Net Income-$14.08M-$24.19M$3.52B$391.27M
7 Day Performance-17.56%-7.23%-5.35%-4.55%
1 Month Performance-19.14%-4.94%-3.62%-5.89%
1 Year Performance-95.55%-4.60%-0.62%-7.84%

Ernexa Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ERNA
Ernexa Therapeutics
2.336 of 5 stars
$1.69
+0.6%
$30.00
+1,675.1%
-95.6%$2.86MN/AN/A5
TCRX
TScan Therapeutics
3.4763 of 5 stars
$0.21
+11.1%
$2.67
+1,169.8%
-85.4%$12.81M$10.32MN/A142
BOLT
Bolt Biotherapeutics
3.7049 of 5 stars
$6.54
-0.5%
$14.50
+121.7%
+33.0%$12.66M$7.70MN/A23
HIND
Vyome
2.9293 of 5 stars
$1.73
-2.0%
$3.50
+101.8%
-67.6%$12.42M$320KN/A18
SYBX
Synlogic
N/A$1.00
flat
N/A-34.5%$12.25M$8KN/A80

Related Companies and Tools


This page (NASDAQ:ERNA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners